Progenra, Inc.
Records under this name other than the patents Progenra, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 6 of 6 · Back to Progenra, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,382,574 | Di- and poly-ubiquitin deubiquitinase substrates and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,680,139 | Anti-neoplastic compounds, compositions and methods Lapsed on the fee record Ended Mar 25, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 25, 2026 | From the USPTO record |
| US 11,273,154 | Azole compounds as ubiquitin-specific protease USP7 inhibitors Lapsed on the fee record Ended Mar 15, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 15, 2026 | From the USPTO record |
| US 8,518,660 | Di- and poly-ubiquitin deubiquitinase substrates and uses thereof Formerly held Lapsed on the fee record Ended Aug 27, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 27, 2025 | From the USPTO record |
| US 9,717,717 | Methods of Treating Cancer Through the Inhibition of USP7 and Immune System Modulation Formerly held Lapsed on the fee record Ended Aug 1, 2025 · High confidence | Lapsed on the fee record | Ended Aug 1, 2025 | High confidence |
| US 7,842,460 | Method for assessing proteolytic enzyme activity using ubiquitin fusion substrate Lapsed on the fee record Ended Nov 30, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 30, 2022 | From the USPTO record |